- Home
- NVT vs ASND Comparison
NVT vs ASND Comparison
Compare NVT & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVT
- ASND
- Stock Information
- Founded
- NVT 1903
- ASND 2006
- Country
- NVT United Kingdom
- ASND Denmark
- Employees
- NVT N/A
- ASND N/A
- Industry
- NVT Industrial Machinery/Components
- ASND Biotechnology: Pharmaceutical Preparations
- Sector
- NVT Industrials
- ASND Health Care
- Exchange
- NVT Nasdaq
- ASND Nasdaq
- Market Cap
- NVT 16.0B
- ASND 12.2B
- IPO Year
- NVT N/A
- ASND 2015
- Fundamental
- Price
- NVT $109.13
- ASND $196.70
- Analyst Decision
- NVT Strong Buy
- ASND Strong Buy
- Analyst Count
- NVT 11
- ASND 17
- Target Price
- NVT $103.45
- ASND $245.76
- AVG Volume (30 Days)
- NVT 2.4M
- ASND 377.7K
- Earning Date
- NVT 10-31-2025
- ASND 11-12-2025
- Dividend Yield
- NVT 0.73%
- ASND N/A
- EPS Growth
- NVT 6.36
- ASND N/A
- EPS
- NVT 3.64
- ASND N/A
- Revenue
- NVT $3,578,600,000.00
- ASND $576,332,355.00
- Revenue This Year
- NVT $27.44
- ASND $104.98
- Revenue Next Year
- NVT $12.69
- ASND $79.91
- P/E Ratio
- NVT $30.23
- ASND N/A
- Revenue Growth
- NVT 21.54
- ASND 54.50
- 52 Week Low
- NVT $41.71
- ASND $118.03
- 52 Week High
- NVT $117.52
- ASND $216.45
- Technical
- Relative Strength Index (RSI)
- NVT 59.22
- ASND 42.98
- Support Level
- NVT $108.50
- ASND $196.86
- Resistance Level
- NVT $113.48
- ASND $209.00
- Average True Range (ATR)
- NVT 3.64
- ASND 6.83
- MACD
- NVT 0.44
- ASND -1.10
- Stochastic Oscillator
- NVT 61.47
- ASND 11.95
About NVT nVent Electric plc
NVent is a leading global provider of electrical connection and protection solutions that touch a broad range of end markets, including infrastructure, industrial, commercial, and residential. NVent designs, manufactures, markets, installs, and services a portfolio of electrical enclosures and electrical fastening solutions. North America accounts for the majority of sales.
About ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.